GPCR
HEALTHCAREStructure Therapeutics Inc
$40.84-0.26 (-0.63%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving GPCR Today?
No stock-specific AI insight has been generated for GPCR yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$15.80$94.90
$40.84
Fundamentals
Market Cap$2.9B
P/E Ratio—
EPS$-2.40
Dividend Yield—
Dividend / Share—
ROE-0.1%
Profit Margin—
Debt / Equity—
Trading
Volume867K
Avg Volume (10D)—
Shares Outstanding71.1M
GPCR News
21 articles- Structure Therapeutics Reports First Quarter 2026 Financial Results and Recent HighlightsYahoo Finance·May 7, 2026
- Why Structure Therapeutics (GPCR) Is Down 7.2% After Strong Oral GLP-1 Phase 2 Data And FDA PlansYahoo Finance·May 3, 2026
- Here is Why Structure Therapeutics (GPCR) is One of the Top Biotech Names to Look atYahoo Finance·Apr 29, 2026
- Structure Therapeutics to Present Aleniglipron, Amylin and Combination Data at the American Diabetes Association 86th Scientific SessionsYahoo Finance·Apr 27, 2026
- LLY's Oral GLP-1 Pill Foundayo Shows Heart Benefits in Diabetes StudyYahoo Finance·Apr 17, 2026
- 3 Ways to Invest in the Growing GLP-1 Weight Loss MarketMarketbeat·Apr 17, 2026
- LLY Stock Down as FDA Asks for More Safety Data on Oral Obesity PillYahoo Finance·Apr 16, 2026
- How Will Mounjaro and Zepbound Sales Aid LLY's Upcoming Q1 Results?Yahoo Finance·Apr 16, 2026
- Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General CounselYahoo Finance·Apr 14, 2026
- Does NVO Face Rising Competitive Pressure on LLY's Foundayo Approval?Yahoo Finance·Apr 14, 2026
- Assessing Structure Therapeutics (GPCR) Valuation After Recent Share Price WeaknessYahoo Finance·Apr 9, 2026
- Nxera Pharma Achieves Second Development Milestone in Collaboration with Eli Lilly Targeting Metabolic DiseasesGlobeNewswire Inc.·Apr 8, 2026
- Guggenheim Remains Bullish on Eli Lilly (LLY) Ahead of Q1 2026 ResultsYahoo Finance·Apr 8, 2026
- How to Play Lilly Stock Post Oral Obesity Pill Foundayo's ApprovalYahoo Finance·Apr 6, 2026
- LLY Stock Up on GLP-1 Pill Approval: Can it Outpace NVO's Wegovy Pill?Yahoo Finance·Apr 2, 2026
- These 5 Biotechs Could Be the Next Big GLP-1 Acquisition Target247 Wall St·Apr 1, 2026
- Structure Therapeutics Phase 2 Obesity Data Shifts Focus To Phase 3Yahoo Finance·Mar 29, 2026
- NVO vs. GPCR: Which Obesity Stock is the Better Buy Right Now?Yahoo Finance·Mar 23, 2026
- Structure Therapeutics Slides 28% This Year as $6 Million Stake EmergesMotley Fool·Mar 22, 2026
- Eli Lilly Confirms 'Superior Weight Loss' Of Its Next-Generation Obesity DrugYahoo Finance·Mar 19, 2026
- Why Did Eli Lilly Stock Slide 6% Despite Strong GLP-1 Momentum?Yahoo Finance·Mar 18, 2026
All 21 articles loaded
Price Data
Open$43.16
Previous Close$41.10
Day High$44.78
Day Low$40.83
52 Week High$94.90
52 Week Low$15.80
52-Week Range
$15.80$94.90
$40.84
Fundamentals
Market Cap$2.9B
P/E Ratio—
EPS$-2.40
Dividend Yield—
Dividend / Share—
ROE-0.1%
Profit Margin—
Debt / Equity—
Trading
Volume867K
Avg Volume (10D)—
Shares Outstanding71.1M
About Structure Therapeutics Inc
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company is headquartered in South San Francisco, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—